Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protara Therapeutics (TARA) Non-Current Deferred Tax Liability (2019 - 2023)

Protara Therapeutics' Non-Current Deferred Tax Liability history spans 5 years, with the latest figure at $1.6 million for Q4 2023.

  • Quarterly Non-Current Deferred Tax Liability rose 7240.91% to $1.6 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Dec 2023, up 7240.91% year-over-year, with the annual reading at $1.6 million for FY2023, 7240.91% up from the prior year.
  • Non-Current Deferred Tax Liability came in at $1.6 million for Q4 2023, up from -$22000.0 in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $1.6 million in Q4 2023 to a low of -$22000.0 in Q4 2022.
  • The 5-year median for Non-Current Deferred Tax Liability is $322000.0 (2020), against an average of $684400.0.
  • Year-over-year, Non-Current Deferred Tax Liability surged 16000.0% in 2020 and then crashed 101.42% in 2022.
  • Protara Therapeutics' Non-Current Deferred Tax Liability stood at $2000.0 in 2019, then soared by 16000.0% to $322000.0 in 2020, then soared by 381.06% to $1.5 million in 2021, then plummeted by 101.42% to -$22000.0 in 2022, then skyrocketed by 7240.91% to $1.6 million in 2023.
  • Per Business Quant, the three most recent readings for TARA's Non-Current Deferred Tax Liability are $1.6 million (Q4 2023), -$22000.0 (Q4 2022), and $1.5 million (Q4 2021).